Zimmermann J - Search Results

1

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.

Capdeville R, Buchdunger E, Zimmermann J, Matter A. Capdeville R, et al. Among authors: zimmermann j. Nat Rev Drug Discov. 2002 Jul;1(7):493-502. doi: 10.1038/nrd839. Nat Rev Drug Discov. 2002. PMID: 12120256 Review.

2

Imatinib: a selective tyrosine kinase inhibitor.

Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T, Zimmermann J. Manley PW, et al. Among authors: zimmermann j. Eur J Cancer. 2002 Sep;38 Suppl 5:S19-27. doi: 10.1016/s0959-8049(02)80599-8. Eur J Cancer. 2002. PMID: 12528769 Review.

3

Tyrosine kinase inhibitors: from rational design to clinical trials.

Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J. Traxler P, et al. Among authors: zimmermann j. Med Res Rev. 2001 Nov;21(6):499-512. doi: 10.1002/med.1022. Med Res Rev. 2001. PMID: 11607931 Review.

4

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB. Buchdunger E, et al. Among authors: zimmermann j. Cancer Res. 1996 Jan 1;56(1):100-4. Cancer Res. 1996. PMID: 8548747

5

Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Regenass U, Lydon NB. Buchdunger E, et al. Among authors: zimmermann j. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2558-62. doi: 10.1073/pnas.92.7.2558. Proc Natl Acad Sci U S A. 1995. PMID: 7708684 Free PMC article. Retracted.

6

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Druker BJ, et al. Among authors: zimmermann j. Nat Med. 1996 May;2(5):561-6. doi: 10.1038/nm0596-561. Nat Med. 1996. PMID: 8616716

7

CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.

Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ. Carroll M, et al. Among authors: zimmermann j. Blood. 1997 Dec 15;90(12):4947-52. Blood. 1997. PMID: 9389713 Free article.

8

Retractions.

Buchdunger E, Trinks U, Mett H, Regenass U, Meyer T, McGlynn E, Pinna LA, Traxler P, Lydon NB, Zimmermann J. Buchdunger E, et al. Among authors: zimmermann j. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):12069. doi: 10.1073/pnas.95.20.12069-a. Proc Natl Acad Sci U S A. 1998. PMID: 9786782 Free PMC article. No abstract available.

9

Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.

Ruetz S, Fabbro D, Zimmermann J, Meyer T, Gray N. Ruetz S, et al. Among authors: zimmermann j. Curr Med Chem Anticancer Agents. 2003 Jan;3(1):1-14. doi: 10.2174/1568011033353605. Curr Med Chem Anticancer Agents. 2003. PMID: 12678910 Review.

10

2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.

Imbach P, Capraro HG, Furet P, Mett H, Meyer T, Zimmermann J. Imbach P, et al. Among authors: zimmermann j. Bioorg Med Chem Lett. 1999 Jan 4;9(1):91-6. doi: 10.1016/s0960-894x(98)00691-x. Bioorg Med Chem Lett. 1999. PMID: 9990463

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,118 results

Search Page